drugset
Drugs / VRC-HIVDNA009-00-VP
last change Dec 2012 re-read 9 days ago

VRC-HIVDNA009-00-VP

also known as VRC-HVDNA 009-00-VP

Vaccine

Developed for
HIV infectious disease
Investigated by
National Institute of Allergy and Infectious Diseases (NIAID) · HIV Vaccine Trials Network

Trials 7

today NCT00125099 · Ph 1/2 NCT00384787 · Ph 1 NCT01549470 · Ph 1 NCT00270218 · Ph 1 NCT00071851 · Ph 1/2 NCT00069030 · Ph 1 NCT00047931 · Ph 1
2003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 15 trials
Phase 1 NCT00384787 Nov 2006 → Nov 2008 HIV infectious disease National Institute of Allergy and Infectious Diseases (NIAID) Completed No outcome recorded
Phase 1 NCT00270218 Feb 2006 → Aug 2007 HIV infectious disease National Institute of Allergy and Infectious Diseases (NIAID) Completed No outcome recorded
Phase 1 NCT00069030 Dec 2003 → Dec 2006 HIV infectious disease National Institute of Allergy and Infectious Diseases (NIAID) Completed No outcome recorded
Phase 1 NCT00047931 Oct 2002 → May 2009 HIV infectious disease National Institute of Allergy and Infectious Diseases (NIAID) Completed No outcome recorded
Phase 1 NCT01549470 ? → Mar 2006 HIV infectious disease National Institute of Allergy and Infectious Diseases (NIAID) Completed No outcome recorded
Phase 1/22 trials
Phase 1/2 NCT00071851 Dec 2003 → Oct 2005 HIV infectious disease National Institute of Allergy and Infectious Diseases (NIAID) Completed No outcome recorded
Phase 1/2 NCT00125099 ? → Sep 2007 HIV infectious disease National Institute of Allergy and Infectious Diseases (NIAID) Completed No outcome recorded

Evidence & citations 4 cited values

Every value below carries the sentence it was read from. 9 sources stand behind the page.

FieldValueCited text
Known as VRC-HIVDNA009-00-VP ClinicalTrials.gov intervention name — accepted as the source's own label NCT00270218 ↗
6

NCT00047931 ↗

NCT00384787 ↗

NCT01549470 ↗

NCT00069030 ↗

NCT00071851 ↗

NCT00125099 ↗
Known as VRC-HVDNA 009-00-VP “AIDS Clinical Trials Group (ACTG) A5187 was a phase I/II, randomized, placebo-controlled, double-blinded trial to evaluate the safety and immunogenicity of an HIV-1 DNA vaccine...” PMID 20479938 ↗ May 2010
Modality Vaccine “multiclade HIV-1 DNA candidate vaccine” PMID 17109336 ↗ Nov 2006
Route Intramuscular “by needle-free intramuscular injection” PMID 17109336 ↗ Nov 2006